Patients with pre-existing risk factors, such as diabetes or heart disease, may already have an elevated risk of NAION, making it difficult to determine the drugs direct role
Gradual dose escalation may reduce gastrointestinal symptoms
More serious but less common side effects to watch for at this dose include acute pancreatitis (symptoms: severe abdominal pain radiating to the back, nausea, vomiting), gallbladder problems (symptoms: sudden pain in the upper right abdomen, fever, jaundice), and significant hypoglycemia if combined with certain diabetes medications
Next-generation multi-agonist alternatives Tirzepatide was groundbreaking because it targeted two receptors (GLP-1 and GIP) instead of just one
It belongs to a class of drugs commonly used for patients seeking treatment for type 2 diabetes
Do not double the next dose